Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Abstract: The present invention provides a compound of Formula I wherein R1, R2, R3, R4, R5, R6, R7, and subscripts x and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.

Abstract: The present invention features, inter alia, methods of treating (a) a patient who has been diagnosed with a hematopoietic cancer or (b) a population of patients who have been diagnosed with a hematopoietic cancer with a fixed dose of tamibarotene or a pharmaceutically acceptable salt thereof. The tamibarotene is administered daily, for a prescribed number of days, at 8-14 (e.g., 12 mg/day) regardless of the patient's weight or body surface area, and may be administered as the sole therapeutic agent or in combination with one or more of the additional therapeutic agents described herein.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Abstract: A reinforced plastic container having improved rim planarity. The container has a non-round main body portion integral with a finish portion. The main body portion has a central longitudinal axis and defines a hollow interior of the container. The finish portion has an upper surface defining a rim with a circumference framing a round opening that provides access to the hollow interior of the container, a radially outwardly extending snap bead being adapted to receive and retain a closure and hermetically seal the container and including interrupted portions located around the circumference of the rim, and a plurality of reinforcements located in the interrupted portions of the snap bead and assuring substantial planarity of the upper surface of the rim even when substantial forces act on the container. Each reinforcement has a strut bounded by and centered between a pair of strut indents, with each indent supported by a buttress.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Abstract: Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Abstract: A reinforced plastic container having improved rim planarity. The container has a non-round main body portion integral with a finish portion. The main body portion has a central longitudinal axis and defines a hollow interior of the container. The finish portion has an upper surface defining a rim with a circumference framing a round opening that provides access to the hollow interior of the container, a radially outwardly extending snap bead being adapted to receive and retain a closure and hermetically seal the container and including interrupted portions located around the circumference of the rim, and a plurality of reinforcements located in the interrupted portions of the snap bead and assuring substantial planarity of the upper surface of the rim even when substantial forces act on the container. Each reinforcement has a strut bounded by and centered between a pair of strut indents, with each indent supported by a buttress.

Abstract: The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for the possible inhibition of plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Abstract: Novel compounds of structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of Formula I may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Abstract: Methods of treating malaria comprising administration of compounds of Formula (I?) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Abstract: Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Abstract: A modular and adaptable power system may be used to provide electrical power connections in an industrial work site, such as a mine. The system provides a plug-and-play interchangeable output module that can be quickly and easily disconnected from and reconnected to a separate and independent input/feed-through module. This allows a user to daisy chain multiple input/feed-through modules together, thereby greatly reducing setup time. Output modules can be quickly disconnected and relocated and returned to previous locations and reconnected.

Abstract: A mounting assembly for restricting movement of an electrical harness of a gas turbine engine includes a base, a first channel formed in the base and extending between a first surface and a second surface of the base, and a second channel formed in the base and extending between the first surface and a third surface of the base. The second surface and the third surface are distinct. At least one flexible connector is receivable within the first channel and the second channel. At least a portion of the at least one flexible connector extends about the electrical harness to couple the electrical harness to the base.

Abstract: A mounting assembly for restricting movement of an electrical harness of a gas turbine engine includes a base, a first channel formed in the base and extending between a first surface and a second surface of the base, and a second channel formed in the base and extending between the first surface and a third surface of the base. The second surface and the third surface are distinct. At least one flexible connector is receivable within the first channel and the second channel. At least a portion of the at least one flexible connector extends about the electrical harness to couple the electrical harness to the base.

Abstract: Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same.